• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Sosei (Group)

We are an international biopharmaceutical group focused on the design and development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Our leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next-generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK. “Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). *

 

	Start	1990-01-01 established
	Industry	pharmaceutical
	Industry 2	BIOTECH
	Person	Tamura, Shinichi (Sosei 1999 CEO + Founder before Genentech Japan CEO)
	City	n. a.
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�: Sosei Group Corporation (d/b/a Sosei Heptares). (7/16/19). "Press Release: Sosei Heptares Enters into Multi-target Research Collaboration and License Agreement with Genentech". Tokyo & London.
		Record changed: 2019-07-16

Advertisement

More documents for Sosei (Group)

• [1] MiNA Therapeutics Ltd.. (9/29/20). "Press Release: MiNA Therapeutics Appoints Peter Bains as Chief Business Officer". London....
• [2] Sosei Group Corporation (d/b/a Sosei Heptares). (8/5/19). "Press Release: Sosei Heptares and Takeda Enter into New Strategic Multi-target Research, Development and Commercialization Partnership". Tokyo & London....
• [3] Sosei Group Corporation (d/b/a Sosei Heptares). (7/16/19). "Press Release: Sosei Heptares Enters into Multi-target Research Collaboration and License Agreement with Genentech". Tokyo & London....
• [4] Sosei Group Corporation (d/b/a Sosei Heptares). (2/4/19). "Press Release: Sosei Heptares Announces Medicxi to Invest up to €40 Million in New Collaboration Based on Its Orexin Agonist Program". Tokyo & London....
• [5] OMass Therapeutics Ltd.. (11/27/18). "Press Release: OMass Therapeutics Expands Its Senior Leadership Team"....
• [6] Autolus Therapeutics Ltd.. (6/8/18). "Press Release: Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer". London....
• [7] MSD Research Laboratories. (1/22/18). "Press Release: MSD Research Laboratories Appoints Dr Fiona H. Marshall to Lead UK Discovery Centre". London....
• [8] Heptares Therapeutics Ltd.. (1/19/18). "Press Release: Changes in Executive Management at Sosei. Dr. Fiona Marshall, Executive Vice President and Chief Scientific Officer of Sosei to Leave to Assume New Role Outside the Company". Tokyo & London....
• [9] Heptares Therapeutics Ltd.. (1/10/18). "Press Release: Sosei Subsidiary, Heptares, Enters Drug R&D Collaboration with Imperial College London Focused on Multiple GPCR Disease Target Opportunities in the Gastro-intestinal Tract". Tokyo & London....
• [10] Sosei Group Corporation. (5/18/17). "Press Release: Sosei Subsidiary Heptares to Receive US$5 Million Milestone Payment from Teva". Tokyo....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.